Researchers have discovered a novel biomarker in stable, ambulatory patients with heart failure with preserved ejection fraction (HFpEF), a finding which may lead to earlier diagnoses of HFpEF.

With the American Heart Association’s 2018 Scientific Sessions set for Nov. 10-12 in Chicago, two co-chairs of the programming committee previewed the themes of the meeting, its most anticipated clinical trials and the two new guidelines that will be unveiled.

ScieGen Pharmaceuticals has issued a recall of the blood pressure drug irbesartan after lab testing revealed a carcinogenic impurity, the FDA announced in a MedWatch Safety Alert.

A Stanford- and Apple-led atrial fibrillation study of more than 400,000 U.S. residents—the largest AFib screening effort to date—has entered its final phase of data collection, the company announced Nov. 1. The trial is expected to wrap up early next year.

Hospitals offering transcatheter aortic valve replacement (TAVR) tend to produce the best survival outcomes when both TAVR and surgical AVR (SAVR) caseloads remain high, according to a study published Oct. 31 in JAMA Cardiology.

Kidney dialysis is an independent predictor of mortality in end-stage renal disease (ESRD) patients undergoing transcatheter aortic valve implantation (TAVI), according to a seven-year trial of 2,000 men and women in Karlsruhe, Germany.

A study out of Binghamton University in New York suggests heart rate (HR) and blood pressure (BP) respond to environmental demands by undergoing allostasis rather than homeostasis, adding further evidence to a hypothesis scientists have mulled for years.

Another drug with the potential to lower cholesterol beyond maximally tolerated statin therapy is preparing to enter the marketplace, STAT reported on Oct. 28.